HC Wainwright started coverage on shares of Replimune Group (NASDAQ:REPL) in a research note released on Monday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $26.00 target price on the stock.

REPL has been the topic of a number of other reports. Wedbush reduced their price target on shares of Eiger Biopharmaceuticals from $43.00 to $35.00 and set an outperform rating on the stock in a report on Wednesday, April 24th. Zacks Investment Research upgraded shares of HB Fuller from a sell rating to a hold rating in a report on Wednesday, July 3rd. Six equities research analysts have rated the stock with a buy rating, Replimune Group presently has a consensus rating of Buy and a consensus price target of $24.67.

NASDAQ:REPL opened at $13.13 on Monday. The firm’s 50 day moving average price is $13.57. Replimune Group has a 52 week low of $8.88 and a 52 week high of $23.55. The company has a current ratio of 14.26, a quick ratio of 14.26 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $441.08 million and a PE ratio of -9.87.

A number of hedge funds and other institutional investors have recently made changes to their positions in REPL. Norges Bank bought a new stake in Replimune Group in the 4th quarter valued at $3,350,000. BlackRock Inc. increased its holdings in Replimune Group by 79.9% in the 4th quarter. BlackRock Inc. now owns 716,242 shares of the company’s stock valued at $7,164,000 after acquiring an additional 318,115 shares during the last quarter. Emerald Mutual Fund Advisers Trust increased its holdings in Replimune Group by 13.0% in the 1st quarter. Emerald Mutual Fund Advisers Trust now owns 708,120 shares of the company’s stock valued at $10,778,000 after acquiring an additional 81,642 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Replimune Group by 40.4% in the 1st quarter. Victory Capital Management Inc. now owns 177,090 shares of the company’s stock valued at $2,695,000 after acquiring an additional 50,950 shares during the last quarter. Finally, Emerald Advisers LLC increased its holdings in Replimune Group by 7.1% in the 1st quarter. Emerald Advisers LLC now owns 697,898 shares of the company’s stock valued at $10,622,000 after acquiring an additional 46,428 shares during the last quarter. Institutional investors own 59.58% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.

Featured Article: What is the downside to momentum investing?

Analyst Recommendations for Replimune Group (NASDAQ:REPL)

Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.